BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33399337)

  • 1. PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies.
    Uccella S; Magnoli F; Vivian LF; Marchiori D; Leoni E; Tibiletti MG; Sessa F
    Am J Surg Pathol; 2021 Sep; 45(9):1293-1296. PubMed ID: 33399337
    [No Abstract]   [Full Text] [Related]  

  • 2. Response To: PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies.
    Volaric AK; Gru AA
    Am J Surg Pathol; 2021 Sep; 45(9):1296-1297. PubMed ID: 34081039
    [No Abstract]   [Full Text] [Related]  

  • 3. PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies.
    Volaric A; Bacchi CE; Gru AA
    Am J Surg Pathol; 2020 Oct; 44(10):1353-1366. PubMed ID: 32649320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Syncytial variant of classic Hodgkin lymphoma: Four cases diagnosed with the aid of CD274/programmed cell death ligand 1 immunohistochemistry.
    Kohno K; Sakakibara A; Iwakoshi A; Hasegawa M; Adachi S; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Takahashi E; Ohashi A; Satou A; Kato S; Asano N; Nakamura S
    Pathol Int; 2020 Feb; 70(2):108-115. PubMed ID: 31894892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease.
    Tiemann M; Samoilova V; Atiakshin D; Buchwalow I
    BMC Res Notes; 2020 Mar; 13(1):139. PubMed ID: 32143684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma.
    Hollander P; Amini RM; Ginman B; Molin D; Enblad G; Glimelius I
    PLoS One; 2018; 13(9):e0204870. PubMed ID: 30261066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced PD-L1 expression on tumor cells in primary cutaneous large T-cell lymphoma with CD30 expression as classic Hodgkin lymphoma mimics: A report of lymph node lesions of two cases.
    Takahashi E; Tsuchida T; Baba S; Tsuzuki T; Shimauchi T; Tokura Y; Tamada Y; Nakamura S
    Pathol Int; 2020 Oct; 70(10):804-811. PubMed ID: 32783303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.
    Tanaka Y; Maeshima AM; Nomoto J; Makita S; Fukuhara S; Munakata W; Maruyama D; Tobinai K; Kobayashi Y
    Eur J Haematol; 2018 May; 100(5):511-517. PubMed ID: 29377256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble PD-1 and PD-L1 as potential biomarkers for classical Hodgkin lymphoma.
    da Silva PB; Real JM; Ferreira LRP; Esteves GH; Brito FDN; Baiocchi OCG
    Hematol Oncol; 2018 Oct; 36(4):709-712. PubMed ID: 30146693
    [No Abstract]   [Full Text] [Related]  

  • 10. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.
    Gerhard-Hartmann E; Goergen H; Bröckelmann PJ; Mottok A; Steinmüller T; Grund J; Zamò A; Ben-Neriah S; Sasse S; Borchmann S; Fuchs M; Borchmann P; Reinke S; Engert A; Veldman J; Diepstra A; Klapper W; Rosenwald A
    Br J Haematol; 2022 Jan; 196(1):116-126. PubMed ID: 34520052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
    Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
    J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Utility of STAT6 and pSTAT6 Immunohistochemistry for Distinguishing Classic Hodgkin Lymphoma and Peripheral T-Cell Lymphoma With Hodgkin and Reed-Sternberg-like Cells.
    Satou A; Takahara T; Yamashita D; Seki M; Kato S; Tanioka F; Tsuyuki T; Wada E; Sakurai K; Karube K; Tsuzuki T; Nakamura S
    Am J Surg Pathol; 2023 Aug; 47(8):897-906. PubMed ID: 37248961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma.
    Hollander P; Ginman B; Molin D; Enblad G; Amini RM; Glimelius I
    Immunobiology; 2020 Jan; 225(1):151872. PubMed ID: 31787352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
    Panjwani PK; Charu V; DeLisser M; Molina-Kirsch H; Natkunam Y; Zhao S
    Hum Pathol; 2018 Jan; 71():91-99. PubMed ID: 29122656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.
    Sakakibara A; Kohno K; Ishikawa E; Suzuki Y; Tsuyuki Y; Shimada S; Shimada K; Satou A; Takahara T; Ohashi A; Takahashi E; Kato S; Nakamura S; Asano N
    J Clin Exp Hematop; 2021 Dec; 61(4):182-191. PubMed ID: 34511582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced PD-L1 expression on tumor cells in primary CD30-positive cutaneous large T-cell lymphoma: a report of lymph node lesions of four cases.
    Takahashi E; Imai H; Tsuyuki Y; Taniguchi N; Kogure Y; Kataoka K; Tsuchida T; Baba S; Tsuzuki T; Shimauchi T; Nakamura S
    J Clin Exp Hematop; 2023; 63(1):49-57. PubMed ID: 36990776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic utility of programmed cell death ligand 1 (clone SP142) in mediastinal composite lymphoma: A report of two cases.
    Sakakibara A; Kohno K; Iwakoshi A; Moritani S; Fujishiro A; Kito K; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Takahashi E; Ohashi A; Satou A; Kato S; Asano N; Nakamura S
    Pathol Int; 2020 Feb; 70(2):116-122. PubMed ID: 31894883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.
    Gravelle P; Burroni B; Péricart S; Rossi C; Bezombes C; Tosolini M; Damotte D; Brousset P; Fournié JJ; Laurent C
    Oncotarget; 2017 Jul; 8(27):44960-44975. PubMed ID: 28402953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
    Fernandez SV; MacFarlane AW; Jillab M; Arisi MF; Yearley J; Annamalai L; Gong Y; Cai KQ; Alpaugh RK; Cristofanilli M; Campbell KS
    Breast Cancer Res; 2020 Dec; 22(1):134. PubMed ID: 33267869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.